In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of ...

“I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular ...

US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery. Waltham, Massachusett ...

chief medical officer of CNS Pharmaceuticals, “the fact that this study showed no cardiotoxicity with Berubicin, even in those receiving the drug for over a year, suggests Berubicin could be a ...

“I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular ...

We are exploring further Berubicin development as well as evaluating opportunities for applying the methodology and strategy from this program to other drugs for CNS malignancies, including our ...